Lilly’s Prasugrel No Match For Clots Compared To Plavix, Bristol Says
This article was originally published in The Pink Sheet Daily
Executive Summary
In contrast to Lilly, Bristol management says it expects FDA to schedule an advisory committee review for the Plavix competitor.
You may also be interested in...
Bristol Sells ConvaTec Wound Care For $4.1 Billion
Sale represents Bristol’s latest effort to sharpen its focus on drugs.
Bristol Sells ConvaTec Wound Care For $4.1 Billion
Sale represents Bristol’s latest effort to sharpen its focus on drugs.
North American Erbitux Sales Up 17 Percent In First Quarter
Positive clinical trial data, increased promotional efforts with partner Bristol-Myers Squibb drive gains, ImClone reports.